ClinicalTrials.gg
RecruitingNCT05296577Updated Oct 16, 2026

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

A Phase 2 interventional study of anlotinib and vinorelbine and Vinorelbine injection in Breast Cancer, sponsored by Henan Cancer Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Henan Cancer Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.
Updated Oct 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing anlotinib in Breast Neoplasms — 10 open to participants now, 11 under way, none of them phase 3. anlotinib · Breast Neoplasms.

Planned enrollment
Largest of 16
134 · median 40
Started
2022
with 1 other
Phase 2
13 of 16
8 open now
Primary completion
2027-09
later than 8 of 10 live
Registered
8th of 16
by date
Lead sponsor
1 of 16
Henan Cancer Hospital

Among the 16 studies testing anlotinib in Breast Neoplasms, this one has the largest planned enrollment, is one of 2 that started in 2022, is one of 13 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 8th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

10 of the 16 studies testing anlotinib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About anlotinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing anlotinib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of anlotinib combined with vinorelbine in the treatment of HER2- advanced breast cancer.

Read the detailed description

The eligible patients were HER2 negative advanced breast cancer patients who experienced failure of previous treatments with anthracyclines and/or taxanes , or hormone receptor-positive HER2-negative advanced breast cancer patients who progressed after at least first-line endocrine therapy in the advanced stage.The enrolled patients would receive anlotinib 12mg orally (2 weeks on/1 week off ,Q3W) plus vinorelbine 25-30mg/m2 intravenously (D1/8,21 days as a cycle) or vinorelbine 25-30mg/m2 intravenously (D1/8,21 days as a cycle).Imaging will be performed after the twice anlotinib administration as 2 cycles.This study is a randomized controlled, phase II clinical trial, and the treatment continued until radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • anlotinib
  • vinorelbine
  • HER2 negtive
  • advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Patients voluntarily participated in the study and signed ;
  • 2. Women aged 18 or older;
  • 3. The number of treatment lines shall not exceed 4 lines;
  • 4. Patients with locally advanced or breast cancer diagnosed as -negative by molecular typing;
  • 5. Enrolled patients were HER2-negative breast cancer patients who had failed to prior taxane and/or anthracycline therapy, or patients with hormone receptor-positive HER2-negative advanced breast cancer who had progressed with at least prior endocrine therapy;
  • 6. score is 0 or 1, and the expected survival is not less than 3 months;
  • 7. Patients with as defined in RECIST1.1 criteria;
  • 8. The main organs function well, and the laboratory test indexes meet the following requirements:(1) Routine blood test (no blood transfusion or hematopoietic stimulating factor was used within 7 days before screening) :① (HB) ≥ 90g/L;② (ANC) ≥1.5×109/L;③ (PLT) ≥ 80×109/L;(2) Blood biochemical test (no blood transfusion or albumin within 7 days before screening) :① and AST ≤2.5 × (liver/bone metastasis ≤5 × ULN; Bone metastases ≤5 ULN);② Serum total (TBIL) ≤1.5 × ULN;③ Serum Cr≤1.5×ULN or ≥60 mL /min;(3) Coagulation function test:① Activated partial thrombin time (), international standardized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN;② Doppler ultrasound assessment: left entricular (LVE F)≥ 50%;
  • 9. The patient has the ability to take medication orally;
  • 10. Any toxic side effects of previous chemotherapy have been recovered to ≤CTCAE1 or baseline level;
  • 11. Women of reproductive age must agree to use a highly effective method of during the study period and for 6 months after the last administration of the study drug; Negative serum or urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects;

Exclusion criteria

Exclusion Criteria:

  • 1. Prior treatment with bevacizumab, anlotinib and other antiangiogenic agents;
  • 2. Patients who had previously used Vinorelbine with an interval time of less than 6 months from the end of medication;
  • 3. Interval of less than 3 weeks after radiotherapy or chemotherapy; The interval after endocrine therapy was less than 1 week;
  • 4. Associated diseases/history;(1) hemoptysis occurred within 3 months before enrollment (hemoptysis > 50ml per day); Or bleeding symptoms of significant clinical significance or a clear bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occultation and above, or suffering from vasculitis, etc.;(2) Arteriovenous thrombosis events occurred within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except those who had been cured after intravenous catheterization due to chemotherapy) and pulmonary embolism, etc.;(3) hypertension, which cannot be well controlled by antihypertensive drug therapy (systolic blood pressure \& GT; 140 mmHg or diastolic pressure > 90 mmHg); During the first 6 months of randomization, myocardial infarction, severe/unstable angina, grade 2 or higher cardiac dysfunction, clinically significant ventricular arrhythmias or ventricular arrhythmias, and symptomatic congestive heart failure;(4) Interstitial lung disease, non-infectious pneumonia or uncontrollable systemic diseases (e.g., diabetes, pulmonary fibrosis and acute pneumonia);(5) Renal insufficiency: urine protein ≥ ++ indicated by routine urine examination, or confirmed 24-hour urine protein level ≥1.0g;(6) History of vaccination within 28 days prior to initial study administration or expected live attenuated vaccine vaccination during study period;(7) (HIV) infection or known acquired immunodeficiency syndrome (AIDS); Active hepatitis (, defined as HBV-DNA ≥ 500 IU/ mL; , defined as hcV-RNA higher than the lower limit of assay) or co-infection with hepatitis B and c;(8) Severe infection, including but not limited to bacteremia and severe pneumonia requiring hospitalization, occurred within 4 weeks before the first administration; Active grade 5.0≥2 infection requiring systemic antibiotic treatment within 2 weeks prior to initial administration or unexplained fever during screening/prior to initial administration > 38.5°C (according to the investigator's judgment, fever caused by tumor can be included in the group); Evidence of active tuberculosis infection within 1 year before administration;
  • 5. Have been diagnosed with any other malignant tumor within 3 years prior to entering the study;
  • 6. Thyroid dysfunction;
  • 7. Major operations were performed within 28 days before enrollment, and minor operations were performed within 14 days before enrollment;
  • 8. Subjects who have received or are planning to receive bone marrow transplantation or solid organ transplantation;
  • 9. Peripheral neuropathy ≥ grade 2; Patients with active , cancerous meningitis, spinal cord compression, or diseases of the brain or pia meningiae found by imaging CT or MRI examination at the time of screening (patients with brain metastases who had completed treatment 14 days before enrollment and had stable symptoms could be enrolled, but were confirmed to have no symptoms of cerebral hemorrhage by craniocerebral MRI, CT or venography evaluation);
  • 10. There are significant factors affecting oral drug absorption, such as inability to swallow, chronic diarrhea, and the presence of clinically significant intestinal obstruction.
  • 11. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study period.
  • 12. Patients with other serious physical or mental disorders or abnormal laboratory tests that may increase the risk of study participation or interfere with study results, and who are considered unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    anlotinib and vinorelbine

    anlotinib combined with vinorelbine

    Drug: anlotinib and vinorelbine

  • Placebo comparator
    vinorelbine

    placebo and vinorelbine

    Drug: Vinorelbine injection

Interventions

  • Druganlotinib and vinorelbine

    Drug pages: AnlotinibStudies of AnlotinibAnlotinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VinorelbineStudies of VinorelbineVinorelbine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    anlotinib 12mg orally ,2 weeks on/1 week off ,Q3W; vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.

    Also known as: AL3818 and vinorelbine

  • DrugVinorelbine injection

    vinorelbine 25-30mg/m2 intravenously ,D1/8,21 days as a cycle.Imaging will be performed after the twice anlotinib administration as 2 cycles.

    Also known as: vinorelbine

06

What researchers measure

Primary outcomes

  1. PFS

    progression-free survival

    Time frame: up to 24 months

Secondary outcomes

  1. ORR

    Objective Response Rate

    Time frame: up to 24 months

  2. OS

    overall survival

    Time frame: up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identificationare available following article publication.

Supporting information: Study protocol

Time frame: five years after publication

Access criteria: Please contact Central contact person by Email

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Sep 2027, 65 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 65 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Sep 2024 → Sep 2027 and completion Dec 2024 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2022
First posted
Mar 25, 2022
StartActual
Mar 22, 2022
Primary completionEst.
Sep 1, 2027was Sep 2024
CompletionEst.
Dec 1, 2028was Dec 2024
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 1, 2024→Sep 1, 2027
Oct 16, 2026
Study completion
Dec 1, 2024→Dec 1, 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Sep 1, 2024→Sep 1, 2027
    Study completion Dec 1, 2024→Dec 1, 2028
    + 3 other changes: index terms, verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05296577
Responsible party
Min Yan, MD (Chief physician, Henan Cancer Hospital) — Principal investigator
First posted
Mar 25, 2022
Start date
Mar 22, 2022
Primary completion
Sep 1, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Min Yan
Contact
ym200678@126.com
15713857388
Huimin Lv
Contact
lvhuimin999@163.com
Min Yan
principal investigator · Henan Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anlotinib · Vinorelbine

Start the discussion